Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.72 |
| ▸ | CA9 | Q16790 | 2/20 | 0.72 |
| ▸ | HTT | P42858 | 4/20 | 0.60 |
| ▸ | IL1RN | P18510 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073370 | 0.87 | CA12 (0.59) | CA12CA9HTTIL1RNKEAP1 | |
| SCHEMBL6341836 | 0.86 | LMNA (0.60) | CA12CA9HTTLMNASMN1; SMN2 | |
| SCHEMBL8752463 | 0.84 | CA12 (1.00) | CA12CA9HTTKEAP1LMNA | |
| SCHEMBL6350131 | 0.82 | ALDH1A1 (0.56) | CA12CA9HTTLMNASMN1; SMN2 | |
| SCHEMBL19582053 | 0.82 | HDAC4 (0.57) | HTTLMNASMN1; SMN2CYP1A2CYP19A1 | |
| SCHEMBL19582052 | 0.82 | HDAC4 (0.57) | HTTLMNASMN1; SMN2CYP1A2CYP19A1 | |
| SCHEMBL19598884 | 0.82 | TUBB4A (0.61) | CA12CA9HTTALDH1A1PKM | |
| SCHEMBL17724614 | 0.82 | HDAC3 (0.58) | CA12CA9HTTLMNASMN1; SMN2 | |
| SCHEMBL19581820 | 0.82 | HDAC3 (0.58) | CA12CA9HTTLMNASMN1; SMN2 | |
| SCHEMBL3046360 | 0.81 | CA12 (0.78) | CA12CA9HTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060718-B2 | Arylsulfonanilide ureas | AMGEN INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20030207864-A1 | Arylsulfonanilide ureas | TULARK INC. | 2003-11-06 | — | — | US | disclosed |
| US-6583165-B2 | Anticarcinogenic, -inflammatory and -proliferative agents; viricides; bactericides; vascular restenosis, autoimmune diseases; psoriasis; anticolesterol and -lipemic agents | TULARIK INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1115701-B1 | ARYLSULFONANILIDE UREAS | TULARIK INC (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1285911-A2 | Arylsulfonanilide ureas | Tularik Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20010027211-A1 | Arylsulfonanilide ureas | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| EP-1115701-A1 | ARYLSULFONANILIDE UREAS | Tularik Inc. (US) | 2001-07-18 | — | — | EP | disclosed |
| US-6214880-B1 | LOWERING PLASMA CHOLESTEROL LEVELS AND INHIBITING ABNORMAL CELL PROLIFERATION WITH SAID COMPOUND; TREATMENT OF CANCER, PSORIASIS, VASCULAR RESTENOSIS, INFECTIONS, ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA | TULARIK INC. | 2001-04-10 | — | — | US | disclosed |
| WO-2000017159-A1 | ARYLSULFONANILIDE UREAS | TULARIK INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207864-A1 | Arylsulfonanilide ureas | UTS2R, UACA, UMPS | CA12 4752/4885CA9 3078/4885HTT 1350/4885 |
| US-20010027211-A1 | Arylsulfonanilide ureas | UTS2R, UACA, UMPS | CA12 4752/4885CA9 3078/4885HTT 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.